Core Viewpoint - Sino Medical's TRADENTTM coronary stent balloon dilation catheter has received approval from the Ministry of Food and Drug Safety (MFDS) in South Korea, marking a significant advancement in the treatment of coronary artery stenosis [1][2] Group 1: Product Approval and Features - The TRADENTTM catheter is the first of its kind in the domestic market to receive approval, specifically designed for percutaneous transluminal coronary angioplasty (PTCA) to treat vascular stenosis [1] - The product features a spiral layout of thorn wires on the balloon surface, enhancing its embedding capability while maintaining good passability [1] - The balloon can effectively lock onto calcified plaques and perform 360° plaque stripping, allowing for controlled and efficient pre-treatment [1] Group 2: Clinical Benefits - The approval of the TRADENTTM catheter is expected to improve the shortcomings of conventional balloon dilation catheters, increasing the success rate of lesion dilation [2] - It aims to reduce the risk of complications such as vascular perforation and damage to normal vessel walls, providing physicians with more clinical options [2] - Patients are anticipated to benefit from enhanced clinical outcomes due to the improved design and functionality of the catheter [2]

Core Viewpoint - Sino Medical (688108.SH) has received approval from the Korean Ministry of Food and Drug Safety for its self-developed TRADENTTM coronary artery balloon dilation catheter, marking a significant milestone in its product portfolio expansion in overseas markets [1] Product Approval and Features - The TRADENTTM catheter is designed for the treatment of vascular stenosis during PTCA, featuring a unique "spiral" layout of thorn wires on the balloon surface, which enhances embedding capability while maintaining good passability [1] - Compared to existing plaque-modifying balloons in the market, this product offers more comprehensive plaque coverage and effectively reduces the incidence of dissection [1] Regulatory Approvals and Market Potential - The product has already obtained medical device registration certificates from the National Medical Products Administration of China, as well as from Thailand and Korea [1] - Following its launch in Korea, the product is expected to complement the company's coronary stents and balloons, potentially boosting overseas sales [1] Market Challenges - Sales in international markets may be influenced by uncertainties related to foreign regulations, market environment changes, and exchange rate fluctuations [1]

Core Viewpoint - Sino Medical (688108.SH) has received approval from the Korean Ministry of Food and Drug Safety (MFDS) for its TRADENT TM coronary stent balloon dilation catheter, enhancing its product offerings in overseas markets [1] Group 1: Product Approval - The TRADENT TM coronary stent balloon dilation catheter is designed for the dilation of narrowed coronary arteries [1] - The product has obtained a medical device registration certificate in South Korea, marking a significant milestone for the company [1] Group 2: Market Impact - The registration of the TRADENT TM catheter will effectively increase the variety of products available for sale in the overseas market [1] - Upon its launch in South Korea, the product will complement the company's existing offerings, such as coronary stents and balloons, creating a robust product portfolio [1] - The utilization of the company's overseas channel resources is expected to drive sales growth for its products in international markets [1]

Core Insights - Sino Medical (688108.SH) reported a total revenue of 364 million yuan for Q3 2025, ranking 84th among disclosed peers [1] - The net profit attributable to shareholders was 21.12 million yuan, placing the company 87th among its peers [1] - The net cash inflow from operating activities was 83.97 million yuan [1] Financial Metrics - The latest debt-to-asset ratio is 30.40%, ranking 99th among disclosed peers, an increase of 1.01 percentage points from the previous quarter and 0.31 percentage points from the same period last year [3] - The latest gross profit margin stands at 65.70% [3] - The return on equity (ROE) is 2.34%, ranking 81st among disclosed peers [3] - The diluted earnings per share (EPS) is 0.05 yuan, ranking 97th among peers [3] - The total asset turnover ratio is 0.28 times [3] - The inventory turnover ratio is 1.30 times, ranking 76th among disclosed peers [3] Shareholder Information - The number of shareholders is 29,400, with the top ten shareholders holding a total of 135 million shares, accounting for 32.44% of the total share capital [3] - The largest shareholder is Tianjin Weixin Sunshine Enterprise Management Consulting Co., Ltd., holding 17.2% [3] - Other notable shareholders include Guo Yanchao (5.01%) and Tianjin Sunshine Guangye Enterprise Management Partnership (2.55%) [3]

Core Viewpoint - The announcement emphasizes the integrity and accuracy of the financial report for the third quarter of 2025, ensuring that there are no false records or misleading statements [2][10]. Financial Data - The financial statements for the third quarter of 2025 have not been audited [3][7]. - The report includes major accounting data and financial indicators, although specific figures are not provided in the text [3][4]. Shareholder Information - The report mentions the total number of ordinary shareholders and the situation of the top ten shareholders, but specific details are not disclosed [5]. Meeting and Approval - The third meeting of the supervisory board was held on October 28, 2025, with all three supervisors present, and the meeting complied with relevant laws and regulations [9][10]. - The supervisory board unanimously approved the third quarter report, confirming that the preparation and review processes adhered to legal and internal regulations [10].

赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）第三届监事会第七 次会议通知于 2025 年 10 月 23 日以书面送达等方式通知各位监事。会议于 2025 年 10 月 29 日在北京市海淀区高梁桥斜街 59号中坤大厦 7层公司会议室以现场和通讯相结合的方式召开。 本次会议应出席监事 3人，实际出席监事 3人。本次会议由监事会主席于长春先生召集并主持。 本次会议的召开符合《中华人民共和国公司法》等有关法律、法规、规范性文件及《公司章程》 《监事会议事规则》等的规定，会议召开程序合法有效。 经与会监事认真讨论，审议并通过如下事项： 1、审议通过"关于赛诺医疗科学技术股份有限公司 2025 年第三季度报告的议案" 经与会监事审议，一致通过"关于赛诺医疗科学技术股份有限公司 2025 年第三季度报告 的议案"，同意《赛诺医疗科学技术股份有限公司 2025 年第三季度报告》。 监事会认为：《赛诺医疗科学技术股份有限公司 2025 年第三季度报告》的编制和审议程 序符合相关法律、法规及《公司章程》等内部规章制度的规定；《赛诺医疗科学技术股份有限 公司 2025 年第三季度报告》的内容与格式符合相关规定 ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-051 赛诺医疗科学技术股份有限公司 关于第三届监事会第七次会议决议的公告 经与会监事审议，一致通过"关于赛诺医疗科学技术股份有限公司 2025 年第三 季度报告的议案"，同意《赛诺医疗科学技术股份有限公司 2025 年第三季度报告》。 监事会认为：《赛诺医疗科学技术股份有限公司 2025 年第三季度报告》的编制 和审议程序符合相关法律、法规及《公司章程》等内部规章制度的规定；《赛诺医 疗科学技术股份有限公司 2025 年第三季度报告》的内容与格式符合相关规定，公允 地反映了公司 2025 年前三季度的财务状况和经营成果等事项；《赛诺医疗科学技术 股份有限公司 2025 年第三季度报告》编制过程中，未发现公司参与第三季度报告编 制和审议的人员有违反保密规定的行为；监事会全体成员保证《赛诺医疗科学技术 股份有限公司 2025 年第三季度报告》披露的信息真实、准确、完整，不存在任何虚 假记载、误导性陈述或重大遗漏，并对其内容的真实性、准确性和完整性依法承担 法律责任。 公司《2025 年第三季度报告》的具体内容，详见公司于同日在中国证监会指定 信息披 ...

Group 1 - The core viewpoint of the article highlights Sino Medical's financial performance in Q3 2023, showing a revenue increase and a positive net profit [1] - Sino Medical reported approximately 364 million yuan in revenue for the first three quarters of 2025, representing a year-on-year increase of 14.24% [1] - The net profit attributable to shareholders of the listed company was approximately 21.12 million yuan, with a basic earnings per share of 0.05 yuan [1] Group 2 - As of the report, Sino Medical's market capitalization stands at 8.5 billion yuan [2]

Financial Performance - The company's operating revenue for Q3 2025 reached ¥123,378,511.92, representing a year-on-year increase of 17.73%[3]. - The total profit for the period was ¥10,506,327.09, with a year-to-date total profit of ¥33,516,889.46, reflecting a significant increase of 300.41% compared to the previous year[3][8]. - Net profit attributable to shareholders for Q3 was ¥7,276,401.53, marking a year-on-year growth of 150.51%[3][8]. - Total operating revenue for the first three quarters of 2025 reached ¥363,854,525.58, an increase of 14.3% compared to ¥318,486,443.24 in the same period of 2024[17]. - Net profit for the first three quarters of 2025 was ¥20,719,725.46, a significant recovery from a net loss of ¥14,931,400.83 in the same period of 2024[18]. - The total comprehensive income for the first three quarters of 2025 was ¥20,953,883.99, a recovery from a loss of ¥16,488,648.07 in the same period of 2024[18]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥83,974,895.27, an increase of 68.89% compared to the previous year[3][8]. - Cash inflow from operating activities for the first three quarters of 2025 is 413,401,906.35 CNY, an increase of 8.3% from 379,785,264.54 CNY in the same period of 2024[19]. - Cash outflow for investing activities is 31,015,450.99 CNY, down 66.0% from 91,099,183.91 CNY in the previous year[20]. - Net cash flow from investing activities is -30,981,098.74 CNY, an improvement from -72,000,968.51 CNY in the same period last year[20]. - Cash inflow from financing activities totals 73,934,400.00 CNY, a decrease of 39.3% from 121,906,687.94 CNY in the previous year[20]. - Net cash flow from financing activities is 13,663,827.42 CNY, down 77.0% from 59,422,575.01 CNY year-over-year[20]. - The ending balance of cash and cash equivalents is 357,698,265.28 CNY, compared to 224,939,661.92 CNY at the end of the previous year, reflecting a 59.0% increase[20]. Assets and Liabilities - Total assets increased by 2.94% from the previous year-end, reaching ¥1,338,809,666.31[4]. - Total liabilities increased slightly to ¥406,995,292.36 from ¥402,216,111.69, showing a growth of 1.9%[15]. - Total equity attributable to shareholders rose to ¥900,750,469.58 from ¥866,885,685.69, marking an increase of 3.9%[15]. - Accounts receivable increased to RMB 13,633,071.77 from RMB 7,473,696.25, representing an increase of approximately 82.5%[12]. - Inventory stood at RMB 102,766,470.80, up from RMB 89,505,811.67, indicating an increase of about 14.7%[13]. - Short-term borrowings increased to RMB 91,472,917.17 from RMB 53,049,209.71, marking an increase of approximately 72.2%[13]. Research and Development - Research and development expenses totaled ¥51,600,668.69 for the quarter, a decrease of 13.60% year-on-year, and accounted for 41.82% of operating revenue[3]. - Research and development expenses were ¥92,757,264.16, down from ¥106,407,498.18, indicating a 13% reduction[17]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 29,360[10]. - Tianjin Weixin Sunshine Enterprise Management Consulting Co., Ltd. holds 71,859,417 shares, accounting for 17.27% of the total shares[10]. - The company has not reported any significant changes in the shareholding structure or any related party transactions among the top shareholders[11]. - The company has not received any declarations regarding other shareholders having related party relationships or concerted action agreements[11]. Other Information - The company plans to continue focusing on market expansion and new product development to drive future growth[3]. - The company has not adopted new accounting standards or interpretations for the year 2025[21]. - The report is unaudited and prepared by Sino Medical Science Technology Co., Ltd[19].

Group 1 - The core point of the article highlights that Sino Medical (688108) experienced a significant decline in stock price, closing at 20.51 yuan, down 18.58% on October 29, with a trading volume of 1.585 billion yuan and a turnover rate of 18.62% [2] - The stock was listed on the daily trading alert due to a price drop exceeding 15% [2] - The top five trading departments accounted for a total transaction of 459 million yuan, with net selling amounting to 51.23 million yuan [2] Group 2 - The main buying department was CITIC Securities' Beijing Anwai Street branch, with a purchase amount of 82.34 million yuan, followed by Guotai Junan Securities' headquarters with 43.21 million yuan [3] - The leading selling department was CITIC Securities (Shandong) with a selling amount of 81.63 million yuan [3] - The stock saw a net outflow of 193 million yuan in main funds on the same day [3] Group 3 - Over the past six months, the stock has been on the trading alert list eight times, with an average price increase of 9.28% the day after being listed and an average increase of 31.38% in the following five days [3]